Filspari approved for focal segmental glomerulosclerosis

What this means

Filspari is an oral medication that blocks two key proteins involved in kidney damage, helping reduce protein loss in urine. FDA approved Filspari for treating focal segmental glomerulosclerosis, a rare kidney disease, in both adults and children. This decision gives patients with this condition a new treatment option that may help slow kidney damage and improve outcomes.